Stereotaxis Stock Gains Momentum on European Medical Breakthrough

Stereotaxis, a pioneer in robotic cardiology systems, has achieved a significant milestone in Europe with the inaugural clinical use of its Genesis system in the Netherlands. The technology was successfully deployed for its first procedures at the renowned Erasmus University Medical Center in Rotterdam. This development marks a substantial advance for robot-assisted medicine and raises the question of whether this operational success can translate into lasting gains for the company’s share price.

The European expansion comes at a time of robust financial performance for Stereotaxis. The company reported second-quarter 2025 revenue of $8.8 million, surpassing analyst expectations and representing a striking 95% increase compared to the same period last year. This financial momentum is complemented by strategic progress, with the deployment at Erasmus... Read more...